# Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

> **NCT03839823** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 222 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **COMBINATION_PRODUCT:** Docetaxel / Capecitabine
- **COMBINATION_PRODUCT:** Capecitabine / Vinorelbine
- **COMBINATION_PRODUCT:** Paclitaxel / Gemcitabine
- **DRUG:** Ribociclib
- **DRUG:** Letrozole OR Anastrozole
- **DRUG:** Goserelin

## Key facts

- **NCT ID:** NCT03839823
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-25
- **Primary completion:** 2022-04-12
- **Final completion:** 2023-05-10
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03839823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03839823, "Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03839823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*